Certara Expands Biosimulation Capabilities By Acquiring Applied BioMath

In a strategic move aimed at solidifying its position as a leader in biosimulation for drug development, Certara (CERT), headquartered in Princeton, New Jersey, announced the acquisition of Applied BioMath. This transaction signifies a milestone for Certara, enabling the company to enhance its existing portfolio with cutting-edge model-informed drug discovery and development services.

Enhancing Drug Discovery with Biosimulation

Applied BioMath brings a wealth of expertise in mathematical modeling to the table, which has traditionally played a critical role in expediting and reducing risks in therapeutic research and development (R&D). By integrating Applied BioMath's tools and technologies, Certara CERT is poised to offer more comprehensive solutions to its clients - from drug discovery through to clinical trials and regulatory submissions. These offerings are not only expected to improve the chances of clinical success but also optimize dosing strategies for novel therapies.

Strategic Advantages for Certara

The acquisition represents a significant step for Certara CERT in its journey to advance the practice of biosimulation. The combination of Certara's robust software suite with Applied BioMath's specialized services is projected to generate a powerful synergy. This synergy will cater to an industry that is increasingly relying on quantitative analyses to drive decision-making in drug development, thereby reinforcing Certara's leadership in the field. The introduction of model-informed approaches is indicative of a paradigm shift toward more efficient and precise R&D processes.

Certara, AppliedBioMath, Acquisition